Immitra Bio
Schlieren, Switzerland
◆ Total Raised
$2.6M
◆ Stage
pre-seed
◆ Location
Schlieren, Switzerland
◆ Founded
2021
◆ Team size
1-10
◆ Links
◆ About Immitra Bio
Swiss biotech developing an in-vivo gene editing platform for inherited blood disorders.
◆ What sets it apart
Unlike traditional gene therapies that replace faulty genes, Immitra activates patients' existing dormant 'backup' genes using ultra-small DNA activator sequences, making CRISPR insertion 1,000x more efficient and enabling off-the-shelf, single-day treatments without chemotherapy [3].
◆ Sectors
◆ Business
Modeltransactional
CustomerPharmaceutical companies and healthcare providers for patient access
◆ Notable
- Closed upsized CHF 2.4 million pre-seed financing round led by Backbone Ventures [1]
- Completed in-vitro proof of concept for lead program IB-003 (Pyruvate Kinase Deficiency) in May 2025 [4]
- Received CHF 150,000 non-dilutive grant from Gebert Rüf Stiftung's InnoBooster programme [8]
- ETH Zürich spin-off from a leading CRISPR gene-editing group [3]
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Immitra Bio do?
Swiss biotech developing an in-vivo gene editing platform for inherited blood disorders.
Where is Immitra Bio based?
Immitra Bio is based in Schlieren, Switzerland, founded in 2021.
How much has Immitra Bio raised?
Immitra Bio has raised $2.6M in tracked funding and is currently at the pre-seed stage.
Who has invested in Immitra Bio?
Investors in Immitra Bio include Backbone Ventures, OCCIDENT, Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT and ETH Foundation.